Dr Reddys Laboratories Ltd (RDY) SEC Filing 20-F Annual report for the fiscal year ending Thursday, March 31, 2016

Dr Reddys Laboratories Ltd

CIK: 1135951 Ticker: RDY

View differences made from one year to another to evaluate Dr Reddys Laboratories Ltd's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 20-F Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Dr Reddys Laboratories Ltd.


Assess how Dr Reddys Laboratories Ltd's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Dr Reddys Laboratories Ltd's Definitive Proxy Statement (Form DEF 14A) filed after their 2016 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools
Ticker: RDY
CIK: 1135951
Form Type: 20-F Annual Report
Accession Number: 0001193125-16-630015
Submitted to the SEC: Thu Jun 23 2016 3:27:08 PM EST
Accepted by the SEC: Thu Jun 23 2016
Period: Thursday, March 31, 2016
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: